Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients

Abstract

BackgroundBiomarkers predicting treatment response may be used to stratify patients with pancreatic ductal adenocarcinoma (PDAC) for available therapies. The aim of this study was to evaluate the association of circulating cytokines with FOLFIRINOX response and with overall survival (OS).MethodsSerum samples were collected before start and after the first cycle of FOLFIRINOX from patients with PDAC (n=83) of all disease stages. Overall, 34 circulating cytokines were analyzed with a multiplex immunoassay. In addition, changes in peripheral blood immune cell counts were determined by flow cytometry to correlate with differences in cytokine levels. Chemotherapy response was determined by CT scans with the RECIST 1.1 criteria, as disease control (n=64) or progressive disease (n=19) within eight cycles of FOLFIRINOX.ResultsPatients with high serum IL-1RA concentrations after one cycle of chemotherapy were less likely to have tumor progression during FOLFIRINOX (OR 0.25, P=0.040). Increase of circulating IL-1RA concentrations correlated with increase of total, classical (CD14+CD16-), and non-classical monocytes (CD14-CD16+), and dendritic cells. In multivariable cox regression, including the variables chemotherapy response outcome and baseline CA19-9 level, serum concentrations of IL-7 (HR 2.14, P=0.010), IL-18 (HR 2.00, P=0.020), and MIP-1β (HR 0.51, P=0.025) after one cycle of FOLFIRINOX showed correlations with OS.ConclusionsCirculating IL-1RA, IL-7, IL-18, and MIP-1β concentrations are biomarkers associated with FOLFIRINOX response in PDAC patients, suggesting an important role for specific immune cells in chemotherapy response and PDAC progression. Cytokine-based treatment might improve patient outcome and should be evaluated in future studies.

Advances in IL-7 Research on Tumour Therapy

“…In the meantime, a combination of immunotherapy and other therapeutic agents may be able to reverse the malignant process to some extent while improving the quality of life and survival of cancer patients. Some studies have also suggested that IL-7-based therapy may improve the prognosis of patients, but this idea still needs to be evaluated in more in-depth studies in the future [ 132 ]. The tumour microenvironment is a crucial factor in the development, progression, and prognosis of lung adenocarcinoma.…”

Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer

“…This includes both local cellular immunity responses and systemic soluble mediator networks 35 – 38 . Furthermore, increasing evidence supports the evaluation of cell markers and immune mediators as predictors of response to treatment or mechanisms of disease development 39 – 43 .…”

Unlocking the Potential of Therapy-Induced Cytokine Responses: Illuminating New Pathways in Cancer Precision Medicine

“…Therefore, an analysis of active cytokines in an individual’s cancer microenvironment or tissues during chemotherapy, especially in comparison to the pre-intervention levels or activities, could reveal information about the biological mechanisms operating in the tumor under therapy stress. Such cytokine readouts may correlate with patient clinical outcomes [ 47 , 48 , 49 , 50 ]. Since cytokines are readily detectable in tissue fluids, this approach to precision medicine has an added value for clinical monitoring and decision making.…”